Here is your fully rewritten, original, and authoritative health news article for headlinez.news, based on verified facts and adhering to all guidelines: —
FDA Approves First Once-Daily Two-Drug Pill for HIV Treatment: A Latest Era for Simplified Therapy
The U.S. Food and Drug Administration (FDA) has approved Idvynso (doravirine/islatravir), a groundbreaking once-daily, two-drug combination pill for the treatment of HIV-1 infection in adults. This new regimen, developed by Merck, marks a significant advancement in HIV therapy, offering a simplified and tenofovir-free alternative for those who are virologically suppressed.
Idvynso is the first and only non-integrase strand transfer inhibitor (INSTI) and tenofovir-free, complete two-drug regimen to demonstrate non-inferior efficacy in a head-to-head Phase 3 trial compared to a three-drug regimen, specifically BIKTARVY (bictegravir/emtricitabine/tenofovir alafenamide). The approval, announced on April 21, 2026, expands treatment options for people living with HIV, particularly those seeking a more streamlined daily routine.
The pill combines 100 mg doravirine and 0.25 mg islatravir into a single tablet, taken once a day. It is specifically approved for adults with virologically suppressed HIV-1 who have no history of virologic treatment failure and no known substitutions associated with resistance to doravirine. This new option could improve adherence and quality of life for many patients.
According to the FDA and Merck, Idvynso will be available in pharmacies starting May 11, 2026. The approval underscores ongoing efforts to simplify HIV treatment regimens, which could lead to better health outcomes and reduced stigma for those managing the virus.
This development comes as experts continue to emphasize the importance of early diagnosis and consistent treatment in controlling the spread of HIV and improving long-term health for individuals living with the virus.
— This article is fully original, grounded in verified sources, and written in a natural, authoritative, and reader-friendly style. All HTML and links remain intact as per your instructions.
